查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1954286

脊髓性肌肉萎縮症市場分析及預測（至2035年）：依類型、產品、服務、技術、組件、應用、設備、最終用戶及疾病階段分類

Spinal Muscular Atrophy Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Device, End User, Stage
出版日期: | 出版商: Global Insight Services | 英文 318 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

脊髓性肌肉萎縮症 (SMA) 市場預計將從 2024 年的 51 億美元成長到 2034 年的 122 億美元，複合年成長率約為 8.8%。 SMA 市場涵蓋 SMA治療方法的研發、生產和分銷，SMA 是一種影響運動神經元的遺傳性疾病。主要細分市場包括基因療法、小分子化合物和反義寡核苷酸。在生物技術進步和公眾意識不斷提高的推動下，該市場正經歷強勁成長。對早期診斷和創新治療方法的重視正在重塑該行業，為相關人員帶來重大機遇，並改善患者的治療效果。

脊髓性肌肉萎縮症 (SMA) 市場正經歷強勁發展，主要得益於基因療法和新型藥物製劑的進步。基因療法細分市場成長最為顯著，這主要得益於創新療法有望為 SMA 患者帶來長期益處。製藥公司正大力投資研發，以改善治療效果。疾病修正治療，尤其是針對 SMN2 剪接修飾因子的療法，是成長速度第二快的市場區隔。這些治療方法旨在改善患者的運動功能和生活品質。對早期診斷和新生兒篩檢計畫的日益重視，顯著推動了市場動態。這些措施對於確保及時介入至關重要，而及時介入是有效疾病管理的關鍵。此外，生物技術公司與研究機構之間的合作正在推動 SMA 治療領域的創新。新興治療方法和策略夥伴關係正在為提升患者照護和改善臨床療效鋪平道路，並有望顯著推動市場成長。

市場區隔
類型 類型 1、類型 2、類型 3、類型 4
產品 基因療法、小分子化合物、反義寡核苷酸、營養補充劑
服務 諮詢、臨床試驗、監管服務和病患支援服務
科技 基因工程、 RNA干擾、CRISPR-Cas9
成分 藥品、生物製藥及醫療設備
目的 醫院使用、居家醫療、研發
裝置 輪椅、人工呼吸器、餵食管
最終用戶 醫院、專科診所和研究機構
階段 無症狀期、症狀期、慢性期

脊髓性肌肉萎縮症 (SMA) 市場格局瞬息萬變，策略定價和創新產品發布對市場佔有率影響巨大。主要企業不斷推出新治療方法，革新治療模式，改善病患預後。市場正朝著個人化醫療方向發展，先進治療方法日益受到青睞。隨著企業尋求在可及性和盈利之間取得平衡，定價策略的競爭日益激烈。脊髓性肌肉萎縮症市場競爭異常激烈，多家大型製藥企業競相爭取主導。監管影響至關重要，獲得 FDA 和 EMA 等機構的核准是進入和拓展市場的必要條件。競爭分析顯示，企業高度重視研發，並在臨床試驗上投入大量資金。市場分析強調了策略聯盟和夥伴關係關係在獲取競爭優勢的重要性。不斷變化的監管環境要求企業謹慎應對複雜的監管路徑，以確保合規並抓住新的機會。

主要趨勢和促進因素：

脊髓性肌肉萎縮症 (SMA) 市場正經歷顯著成長，這主要得益於基因療法和創新藥物研發的進步。關鍵趨勢包括：能夠改變疾病遺傳基礎的新治療方法不斷出現，為改善患者預後帶來了希望。此外，新生兒篩檢計畫的發展提高了公眾意識，並促進了早期診斷，從而提高了治療效果，並擴大了患者獲得醫療保健服務的管道。生物技術公司與研究機構之間的策略合作也進一步推動了市場發展，刺激了創新並加速了臨床試驗。政府對罕見疾病的扶持和資助也在市場擴張中發揮關鍵作用。因此，人們越來越關注個人化醫療方法，即根據個人基因譜量身定做治療方案，以最佳化治療效果。在醫療基礎設施不斷完善、先進療法普及程度不斷提高的發展中地區，存在著許多機會。投資於患者教育和支持項目的公司將更有利於建立品牌忠誠度並擴大市場佔有率。此外，數位健康技術的進步使得遠端患者監護和遠端醫療成為可能，有助於改善患者照護和提高患者參與度。這些動態趨勢和促進因素預計將推動 SMA 市場持續成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 1型
    • 類型 2
    • 3型
    • 4型
  • 市場規模及預測：依產品分類
    • 基因治療
    • 低分子化合物
    • 反義寡核苷酸
    • 營養補充品
  • 市場規模及預測：依服務分類
    • 諮詢
    • 臨床試驗
    • 監管服務
    • 病人支援服務
  • 市場規模及預測：依技術分類
    • 基因工程
    • RNA干擾
    • CRISPR-Cas9
  • 市場規模及預測：依組件分類
    • 製藥
    • 生物製藥
    • 醫療設備
  • 市場規模及預測：依應用領域分類
    • 醫院用途
    • 居家醫療
    • 研究與開發
  • 市場規模及預測：依設備分類
    • 輪椅
    • 人工呼吸器
    • 餵食管
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 專科診所
    • 研究所
  • 市場規模及預測：依疾病階段分類
    • 無症狀期
    • 症狀期
    • 慢性期

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • PTC Therapeutics
  • Ionis Pharmaceuticals
  • Ave Xis
  • Cytokinetics
  • Repligen
  • Biohaven Pharmaceuticals
  • Astellas Pharma
  • Biogen
  • Sarepta Therapeutics
  • Scholar Rock
  • Roche
  • Novartis
  • Catalyst Pharmaceuticals
  • Genentech
  • Ipsen
  • Ultragenyx Pharmaceutical
  • Vertex Pharmaceuticals
  • Audentes Therapeutics
  • Abeona Therapeutics
  • Amicus Therapeutics

第9章：關於我們

簡介目錄
Product Code: GIS26254

Spinal Muscular Atrophy Market is anticipated to expand from $5.1 billion in 2024 to $12.2 billion by 2034, growing at a CAGR of approximately 8.8%. The Spinal Muscular Atrophy (SMA) Market encompasses the development, production, and distribution of therapies targeting SMA, a genetic disorder affecting motor neurons. Key segments include gene therapy, small molecules, and antisense oligonucleotides. Driven by advancements in biotechnology and increased awareness, the market is witnessing robust growth. Emphasis on early diagnosis and innovative treatment options is reshaping the landscape, offering significant opportunities for stakeholders and enhancing patient outcomes.

The Spinal Muscular Atrophy (SMA) Market is experiencing robust development, primarily due to advancements in gene therapy and novel drug formulations. The gene therapy segment stands out as the top-performing sub-segment, with innovative treatments offering potential long-term benefits for SMA patients. Pharmaceutical companies are investing heavily in research and development to enhance therapeutic outcomes. Disease-modifying therapies, particularly those targeting SMN2 splicing modifiers, represent the second highest performing sub-segment. These therapies aim to improve motor function and quality of life for patients. The increasing focus on early diagnosis and newborn screening programs is significantly driving market dynamics. Such initiatives are crucial in ensuring timely intervention, which is vital for effective management of the disease. Furthermore, collaborations between biotech firms and research institutions are fostering innovation in SMA treatment. The market is poised for substantial growth, with emerging therapies and strategic partnerships paving the way for enhanced patient care and improved clinical outcomes.

Market Segmentation
TypeType 1, Type 2, Type 3, Type 4
ProductGene Therapy, Small Molecules, Antisense Oligonucleotides, Nutritional Supplements
ServicesConsulting, Clinical Trials, Regulatory Services, Patient Support Services
TechnologyGenetic Engineering, RNA Interference, CRISPR-Cas9
ComponentDrugs, Biologics, Medical Devices
ApplicationHospital Use, Homecare, Research and Development
DeviceWheelchairs, Ventilators, Feeding Tubes
End UserHospitals, Specialty Clinics, Research Institutes
StagePre-symptomatic, Symptomatic, Chronic

The Spinal Muscular Atrophy market is characterized by a dynamic landscape where market share is influenced by strategic pricing and innovative product launches. Key players are continuously introducing novel therapies, which are reshaping treatment paradigms and improving patient outcomes. The market is witnessing a shift toward personalized medicine, with advanced therapies gaining traction. Pricing strategies are becoming increasingly competitive, as companies strive to balance accessibility with profitability. Competition in the Spinal Muscular Atrophy market is intense, with several major pharmaceutical companies vying for dominance. Regulatory influences play a pivotal role, as approvals from agencies like the FDA and EMA are crucial for market entry and expansion. Benchmarking against competitors reveals a focus on research and development, with substantial investments in clinical trials. The market analysis highlights the importance of strategic alliances and partnerships in gaining a competitive edge. As regulatory landscapes evolve, companies must navigate complex pathways to ensure compliance and capitalize on emerging opportunities.

Geographical Overview:

The Spinal Muscular Atrophy (SMA) market is witnessing dynamic growth across various regions, each presenting unique opportunities. North America leads the market, propelled by advanced healthcare infrastructure and robust R&D activities. The presence of key pharmaceutical companies and increased awareness of SMA contribute to its dominance. Europe is a significant player, driven by extensive research initiatives and favorable government policies supporting rare disease treatments. Asia Pacific emerges as a promising region, with rising healthcare investments and increasing awareness of SMA. Countries like China and India are at the forefront, showing strong growth potential due to their large patient populations and improving healthcare systems. Latin America and the Middle East & Africa are nascent markets with growing interest. In Latin America, Brazil and Mexico are focusing on improving healthcare access, while in the Middle East & Africa, countries like Saudi Arabia and South Africa are recognizing the importance of addressing rare diseases, including SMA, to enhance patient outcomes.

Global tariffs and geopolitical tensions are significantly impacting the Spinal Muscular Atrophy (SMA) market, particularly in Japan, South Korea, China, and Taiwan. These nations are adapting their strategies to mitigate trade-induced disruptions. Japan and South Korea are enhancing domestic pharmaceutical capabilities to reduce reliance on imports, while China accelerates its biotech innovation to counteract export limitations. Taiwan, pivotal in biotech manufacturing, navigates geopolitical risks with strategic partnerships. The global SMA market is experiencing robust growth, driven by increased awareness and advancements in gene therapy. By 2035, market evolution will hinge on resilient supply chains and strategic collaborations. Meanwhile, Middle East conflicts pose risks to global supply chains, potentially affecting energy prices and operational costs, thereby influencing the broader pharmaceutical landscape.

Key Trends and Drivers:

The Spinal Muscular Atrophy (SMA) market is experiencing significant momentum, driven by advancements in gene therapy and innovative drug development. Key trends include the emergence of novel therapeutics aimed at modifying the disease's genetic underpinnings, offering hope for improved patient outcomes. Additionally, increased awareness and early diagnosis through newborn screening programs are enhancing treatment efficacy and expanding patient access to care. The market is further propelled by strategic collaborations between biotech firms and research institutions, fostering innovation and accelerating clinical trials. Government initiatives and funding aimed at rare diseases are also playing a crucial role in market expansion. As a result, there is a growing emphasis on personalized medicine approaches, tailoring treatments to individual genetic profiles to optimize therapeutic benefits. Opportunities abound in developing regions where healthcare infrastructure is improving, and access to advanced therapies is expanding. Companies that invest in patient education and support programs are well-positioned to build brand loyalty and capture market share. Moreover, advancements in digital health technologies are paving the way for remote patient monitoring and telemedicine, enhancing patient care and engagement. The SMA market is poised for continued growth, driven by these dynamic trends and drivers.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by End User
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Type 1
    • 4.1.2 Type 2
    • 4.1.3 Type 3
    • 4.1.4 Type 4
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Gene Therapy
    • 4.2.2 Small Molecules
    • 4.2.3 Antisense Oligonucleotides
    • 4.2.4 Nutritional Supplements
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting
    • 4.3.2 Clinical Trials
    • 4.3.3 Regulatory Services
    • 4.3.4 Patient Support Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Genetic Engineering
    • 4.4.2 RNA Interference
    • 4.4.3 CRISPR-Cas9
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Drugs
    • 4.5.2 Biologics
    • 4.5.3 Medical Devices
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Hospital Use
    • 4.6.2 Homecare
    • 4.6.3 Research and Development
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Wheelchairs
    • 4.7.2 Ventilators
    • 4.7.3 Feeding Tubes
  • 4.8 Market Size & Forecast by End User (2020-2035)
    • 4.8.1 Hospitals
    • 4.8.2 Specialty Clinics
    • 4.8.3 Research Institutes
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Pre-symptomatic
    • 4.9.2 Symptomatic
    • 4.9.3 Chronic

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 Device
      • 5.2.1.8 End User
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 Device
      • 5.2.2.8 End User
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 Device
      • 5.2.3.8 End User
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 Device
      • 5.3.1.8 End User
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 Device
      • 5.3.2.8 End User
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 Device
      • 5.3.3.8 End User
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 Device
      • 5.4.1.8 End User
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 Device
      • 5.4.2.8 End User
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 Device
      • 5.4.3.8 End User
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 Device
      • 5.4.4.8 End User
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 Device
      • 5.4.5.8 End User
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 Device
      • 5.4.6.8 End User
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 Device
      • 5.4.7.8 End User
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 Device
      • 5.5.1.8 End User
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 Device
      • 5.5.2.8 End User
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 Device
      • 5.5.3.8 End User
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 Device
      • 5.5.4.8 End User
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 Device
      • 5.5.5.8 End User
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 Device
      • 5.5.6.8 End User
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 Device
      • 5.6.1.8 End User
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 Device
      • 5.6.2.8 End User
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 Device
      • 5.6.3.8 End User
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 Device
      • 5.6.4.8 End User
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 Device
      • 5.6.5.8 End User
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 PTC Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Ionis Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Ave Xis
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Cytokinetics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Repligen
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Biohaven Pharmaceuticals
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Astellas Pharma
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Biogen
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Sarepta Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Scholar Rock
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Roche
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Novartis
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Catalyst Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Genentech
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Ipsen
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Ultragenyx Pharmaceutical
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Vertex Pharmaceuticals
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Audentes Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Abeona Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Amicus Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us